GTx and Tessera form prostate cancer test deal:
This article was originally published in Clinica
Executive Summary
In what could lead to a marriage of therapy and diagnostics for prostate cancer, biopharmaceutical firm GTx has linked up with Tessera to develop a blood or urine test for premalignant prostate lesions that can become cancerous. Under the agreement, Memphis, Tennessee-based GTx will provide clinical samples from its completed phase IIb clinical trial of its Acapodene (toremifene citrate) agent for reducing the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). Tessera's early prostate cancer antigen, ProstaMark, will be used to identify patients with PIN lesions and/or early-stage prostate cancer.